A 94-person intervention trial finds protein intake reduces blood pressure over a maltodextrin supplement.
A Dutch study on 94 overweight adults supports the growing notion that ample dietary protein may alleviate high blood pressure.
Researchers from the Top Institute of Food and Nutrition (Wageningen, the Netherlands) assigned 94 men and women to a protein (20 g of plant and animal protein) or maltodextrin supplement three times daily for four weeks. Diastolic and systolic blood pressure was evaluated periodically for patients, all of whom had elevated, but untreated blood pressure.
Blood pressure readings were evaluated as either office readings or daytime readings.
Compared to readings from the maltodextrin group, systolic blood pressure decreased by 4.9 mm Hg (office) and 4.6 mm Hg (daytime) in the protein group. Diastolic blood pressure dropped 2.7 mm Hg for the protein group over maltodextrin group (office), and daytime readings did not differ between groups.
Human risk of experiencing major cardiovascular events can be reduced with even slight drops in blood pressure, according to experts. The results of this protein trial complement previous intervention studies linking protein intake and blood pressure.
Agglomix (Tilburg, the Netherlands) provided protein and maltodextrin supplements for the study. It is available for further reading at the American Journal of Clinical Nutrition.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Apparo Inc. and Döhler have entered into a joint development agreement
June 12th 2024According to the company’s press release, Apparo’s ability to upcycle protein and other nutritional ingredients, combined with Döhler’s large pipeline of applications, will help the company better meet the evolving demands of the food and beverage sector.